Search engine for discovering works of Art, research articles, and books related to Art and Culture
Javascript must be enabled to continue!
Successful management of therapy‐related chronic myelomonocytic leukemia with cytarabine, aclarubicin, and azacitidine following tegafur/gimeracil/oteracil
View through CrossRef
AbstractA 55‐year‐old man was diagnosed with therapy‐related chronic myelomonocytic leukemia (t‐CMML) after exposure to tegafur/gimeracil/oteracil. Although he was refractory to hydroxyurea and low‐dose cytarabine, combination therapy with cytarabine, aclarubicin and azacitidine (CA‐AZA) provided good disease control, and he underwent allogeneic stem cell transplantation. This report has two key massages. First, tegafur/gimeracil/oteracil may have a potential risk of developing t‐CMML. Second, CA‐AZA therapy may be considered as a therapeutic option for patients with t‐CMML.
Title: Successful management of therapy‐related chronic myelomonocytic leukemia with cytarabine, aclarubicin, and azacitidine following tegafur/gimeracil/oteracil
Description:
AbstractA 55‐year‐old man was diagnosed with therapy‐related chronic myelomonocytic leukemia (t‐CMML) after exposure to tegafur/gimeracil/oteracil.
Although he was refractory to hydroxyurea and low‐dose cytarabine, combination therapy with cytarabine, aclarubicin and azacitidine (CA‐AZA) provided good disease control, and he underwent allogeneic stem cell transplantation.
This report has two key massages.
First, tegafur/gimeracil/oteracil may have a potential risk of developing t‐CMML.
Second, CA‐AZA therapy may be considered as a therapeutic option for patients with t‐CMML.
Related Results
Effect of Sipjeondaebo-Tang on the Pharmacokinetics of S-1, an Anticancer Agent, in Rats Evaluated by Population Pharmacokinetic Modeling
Effect of Sipjeondaebo-Tang on the Pharmacokinetics of S-1, an Anticancer Agent, in Rats Evaluated by Population Pharmacokinetic Modeling
S-1 (TS-1®) is an oral fluoropyrimidine anticancer agent containing tegafur, oteracil, and gimeracil. Sipjeondaebo-tang (SDT) is a traditional oriental herbal medicine that has pot...
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract
A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Aclarubicin Reduces the Nuclear Mobility of Human DNA Topoisomerase IIβ
Aclarubicin Reduces the Nuclear Mobility of Human DNA Topoisomerase IIβ
DNA topoisomerase II (TOP2) is an enzyme that resolves DNA topological problems arising in various nuclear processes, such as transcription. Aclarubicin, a member of the anthracycl...
Additional Decitabine Did Not Improve Outcomes of Elder Acute Myeloid Leukemia Patients Based on Microtransplantation with Cytarabine and Anthracycline Chemotherapy
Additional Decitabine Did Not Improve Outcomes of Elder Acute Myeloid Leukemia Patients Based on Microtransplantation with Cytarabine and Anthracycline Chemotherapy
Abstract
Acute myeloid leukemia (AML) of older patients is an aggressive malignancy. Despite decitabine is performed some clinic trials in these patients, however th...
Myosin-IIa Is Required for Leukemia Cell Extravasation and Its Inhibition Reduces Leukemia Dissemination and Prolongs Survival in a Mouse Model of Acute Lymphoblastic Leukemia
Myosin-IIa Is Required for Leukemia Cell Extravasation and Its Inhibition Reduces Leukemia Dissemination and Prolongs Survival in a Mouse Model of Acute Lymphoblastic Leukemia
Abstract
Background: Leukemia affects approximately 45,000 people each year in the USA with more than 20,000 fatalities. Many leukemia patients experience initial re...
Hemophagocytic lymphohistiocytosis as an unexpected complication of Venetoclax+Azacitidine in Acute Myeloid Leukemia
Hemophagocytic lymphohistiocytosis as an unexpected complication of Venetoclax+Azacitidine in Acute Myeloid Leukemia
Background: Venetoclax is a drug that targets BCL-2 protein in cancer cells, first approved for chronic lymphocytic leukemia, this drug has showed efficacy also in acute myeloid le...
Recurrent cytarabine-induced sinus bradycardia in a patient with acute myeloid leukemia: a case report and review of the literature
Recurrent cytarabine-induced sinus bradycardia in a patient with acute myeloid leukemia: a case report and review of the literature
Abstract
Background
Cytarabine is a pyrimidine nucleoside analog that plays a crucial role in the treatment of acute myel...
FAS Gene Expression Is Epigenetically Regulated and Predicts the Responsiveness to Azacitidine In High-Risk Myelodysplastic Syndromes
FAS Gene Expression Is Epigenetically Regulated and Predicts the Responsiveness to Azacitidine In High-Risk Myelodysplastic Syndromes
Abstract
Abstract 232
Background:
Low risk myelodysplastic syndromes (MDS) CD34-positive cells exhibit high level...